BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia

Journal of Clinical Pathology

Volumn 69, Issue 9, 2016, Pages 817-821

  Latham, Susan ^a   Bartley, Paul A ^a   Budgen, Bradley ^a   Ross, David M ^a,b   Hughes, Elizabeth ^a   Branford, Susan ^c   White, Deborah ^d   Hughes, Timothy P ^b   Morley, Alexander A ^a,e  

^a FLINDERS UNIVERSITY   (Australia)

^b Haematology Division   (Australia)

^c CENTRE FOR CANCER BIOLOGY   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e Monoquant   (Australia)

Author keywords

cancer genetics; CML; PCR

Indexed keywords

BCR ABL 1 FUSION PROTEIN; HYBRID PROTEIN; IMATINIB; NILOTINIB; UNCLASSIFIED DRUG; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; CLINICAL DECISION MAKING; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; NEOPLASM, RESIDUAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CLINICAL DECISION-MAKING; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84958093178     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-203538     Document Type: Article

References (16)

1. Branford S, Fletcher L, Cross NPC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330-8
2. Bartley PA, Latham S, Budgen B, et al. A DNA Real-Time Quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. J Mol Diag 2015; 17: 185-92
3. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926-32
4. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007; 13: 6136-43
5. Morley AA, Baikie AG, Galton DAG. Cyclic leucocytosis as evidence for retention of normal homoeostatic control in chronic granulocytic leukaemia. Lancet 1967; 2: 1320
6. Clarkson B, Strife A, Wisniewski D, et al. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003; 17: 1211-62
7. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872-84
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukaemia. Version 1, 2015. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site
9. Bianchini M, De Brasi C, Gargallo P, et al. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. Eur J Haematol 2009; 82: 292-300
10. Hanfstein B, Shlyakhto V, Lauseker M, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014; 28: 1988-92
11. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014; 124: 511-18
12. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 7080-5
13. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-35
14. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-22
15. Bartley PA, Ross DM, Latham S, et al. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol 2010; 32: e222-8
16. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 24: 1719-24